Orchestra BioMed Holdings, Inc. (OBIO)

4.9500 +0.0700 (+1.43%) At close: 04:00PM EDT

Orchestra BioMed Holdings, Inc.

150 Union Square Drive
New Hope, PA 18938
United States
212 862 5797
https://orchestrabiomed.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 56

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David P. Hochman	Founder, Chairman of the Board of Directors & CEO	942k	N/A	1975
Mr. Darren R. Sherman	Founder, President, COO & Director	787k	N/A	1971
Mr. Andrew Lawrence Taylor M.B.A.	Chief Financial Officer	326.37k	N/A	1971
Mr. William Reed Little	Executive VP of Corporate Development & Strategy	N/A	N/A	1972
Dr. Yuval Hay Mika D.Sc, Ph.D.	GM & CTO of Bioelectronic Therapies	N/A	N/A	1959
Dr. George Papandreou Ph.D.	GM & Senior VP of Focal Therapies	N/A	N/A	1965
Dr. Hans-Peter Stoll M.D., Ph.D.	Chief Clinical Officer	N/A	N/A	N/A
Dr. Avraham Matityahu Fischer M.D.	Senior Vice President of Medical Affairs & Innovation	N/A	N/A	1956
Mr. Bob Laughner	Senior Vice President of Regulatory & Quality	N/A	N/A	N/A
Mr. Juan Lorenzo	Senior Vice President of Product Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Corporate governance

Orchestra BioMed Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.